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Abstract
Summary This nested case-control analysis of a Swiss
ambulatory cohort of elderly women assessed the discrim-
inatory power of urinary markers of bone resorption and
heel quantitative ultrasound for non-vertebral fractures. The
tests all discriminated between cases and controls, but
combining the two strategies yielded no additional relevant
information.
Introduction Data are limited regarding the combination of
bone resorption markers and heel quantitative bone ultra-
sound (QUS) in the detection of women at risk for fracture.
Methods In a nested case-control analysis, we studied 368
women (mean age 76.2±3.2 years), 195 with low-trauma
non-vertebral fractures and 173 without, matched for age,
BMI, medical center, and follow-up duration, from a
prospective study designed to predict fractures. Urinary total
pyridinolines (PYD) and deoxypyridinolines (DPD) were
measured by high performance liquid chromatography. All
women underwent bone evaluations using Achilles+ and
Sahara heel QUS.
Results Areas under the receiver operating-characteristic
curve (AUC) for discriminative models of the fracture
group, with 95% confidence intervals, were 0.62 (0.56–
0.68) and 0.59 (0.53–0.65) for PYD and DPD, and 0.64
(0.58–0.69) and 0.65 (0.59–0.71) for Achilles+ and Sahara
QUS, respectively. The combination of resorption markers
and QUS added no significant discriminatory information
to either measurement alone with an AUC of 0.66 (0.60–
0.71) for Achilles+ with PYD and 0.68 (0.62–0.73) for
Sahara with PYD.
Conclusions Urinary bone resorption markers and QUS are
equally discriminatory between non-vertebral fracture
patients and controls. However, the combination of bone
resorption markers and QUS is not better than either test
used alone.
Keywords Bone markers . Bone ultrasound . Fracture risk .
Nested case-control study . Osteoporosis
Introduction
Osteoporosis has been recognized as a major public health
problem. In Western countries, hip fracture incidence rates
among white women are the highest worldwide [1]. Since
effective treatments exist to minimize fracture risk, it is
essential that new screening strategies are developed to
detect women at risk. Specific biochemical markers of bone
turnover and ultrasonic measurements of bone have been
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proposed as risk factors that independently add information
in the assessment of fracture probability.
The measurement of bone resorption using urinary
biochemical markers has been studied as a clinical tool
with which to predict fracture risk in postmenopausal
women [2, 3]. In prospective nested case-control analyses
[4–6] and cohort studies [7–10], elevated bone resorption
markers have been found to be associated with an increased
risk of osteoporosis-related fractures. For the identification
of high-risk individuals, combination strategies, using bone
markers, and bone mineral density (BMD) have been
shown to increase test specificity without any loss in
sensitivity [11].
Quantitative ultrasound (QUS) of the calcaneus has been
shown in many prospective studies to predict vertebral and
non-vertebral fracture risk independent of BMD [12–18].
Comparing different QUS in the same population, we
previously demonstrated that two heel QUS devices—the
Achilles+ (GE-Lunar, Madison, WI, USA) and the Sahara
(Hologic, Waltham, MA, USA)—are good predictors of hip
and non-vertebral fracture risk, with no detectable differ-
ence between the two devices [19, 20].
However, few data exist with respect to the combination
of bone resorption markers and heel QUS, in terms of
identifying women at risk for fractures. To investigate this
issue further, we performed nested case-control analysis of
a Swiss cohort of post-menopausal women, comparing the
results obtained using urinary levels of two bone resorption
markers and two heel QUS devices, in women who had
sustained a low-trauma hip or arm fracture versus those
without fractures.
Methods
Subjects
Between the autumn of 1997 and summer of 1999, 7,609
ambulatory Swiss women, with a mean age of 75.3±
3.1 years, were enrolled voluntarily in the Swiss Evaluation
of Methods of Measuring Osteoporotic Fracture Risk
(SEMOF) study [19, 21]. This prospective, multicenter
study compared three different QUS devices—two measur-
ing the heel and one the phalanges—as potential predictors
of non-vertebral fracture risk. The SEMOF study was
financed by the Association of Swiss Health Insurance, and
the protocol was accepted by the Swiss Ethics Committee of
Medical Sciences. Written informed consent was obtained
from all women. Participants were recruited from official
state registries and asked to visit one of the Swiss
osteoporosis center certified to use the QUS devices.
Women able to walk and independent in their daily
activities were included; those with a hip fracture history
or bilateral hip replacement were excluded. At baseline,
participants underwent a face-to-face interview, during
which they were asked about various osteoporosis risk
factors, including personal fracture history, followed by a
clinical examination that included calculation of body mass
index (BMI). All women also underwent heel QUS. After
the baseline visit, all women were asked to send back a
second fasting sample of urine for the measurement of
urinary bone markers. Details of study methods and patient
characteristics have been reported previously [21, 22].
Identification of fractures
According to the protocol of the SEMOF study, information
on vertebral fractures was not collected. We considered
major osteoporotic fractures (excluding vertebral fractures),
defined as low-trauma hip, distal forearm, or proximal
humerus fractures [23]. Low-trauma fractures were defined
as spontaneous or as a consequence of a fall from standing
height or less. A medical report from the patient’s attending
physician was obtained to confirm each fracture. The
validity of fracture information has been demonstrated
previously [24].
Nested case-control design
To assess the predictive power of markers of bone
resorption, 250 women with non-vertebral fractures and
250 controls matched for age, BMI, hospital, and follow-up
duration were selected randomly and included in a nested
case-control study. From the 500 selected women, 406
urine samples were qualitatively and quantitatively analyz-
able. Thirty-eight women were excluded because they were
receiving hormone replacement therapy or antiresorptive
therapy, like a bisphosphonate. Ultimately, 368 women—
195 fracture cases and 173 controls—were included in the
analysis, with a mean age of 76.2±3.2 years and a mean
follow-up of 2.3±1.2 years. Among the 195 fracture cases,
62 were hip fractures and 133 were fractures of the distal
forearm or proximal humerus.
Urine sampling
Urinary samples were collected between the autumn of
1997 and summer of 1999. Each participant in the SEMOF
cohort received a standard plastic container and instructions
on how to collect a urine specimen at home. They were
asked, following standard protocol, to send the fasting
second morning specimen of urine to the Institute for
Clinical Chemistry and Hematology (State Hospital of St.
Gall). To minimize preanalysis variability, samples were
stored frozen at −20°C, light protected, and never thawed
until the analyses were done in 2004.
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Measurement of bone markers
Two crosslinked collagen components, total urinary pyr-
idinoline (PYD) and deoxypyridinoline (DPD), were
measured by high performance liquid chromatography
(HPLC). All analyses were conducted using the same
commercial test kit: the BIO-RAD Pyridinium-Crosslinks
by HPLC, a highly specific technique designed to isolate
and detect pyridinium crosslinks in urine [25]. Briefly, a
150-μl urine sample, mixed with an internal standard, was
hydrolyzed with 200 μl HCL 12 N over 16 h at 100°C.
After dilution, cold samples were applied to a cellulose
column for extraction of interfering substances, and
pyridinium crosslinks were eluted from the column. For
HPLC analysis, separation of PYD and DPD was obtained
by chromatography on a reverse phase column with
isocratic elution. The elements’ natural fluorescence was
detected by spectrofluorometry. Quantitative determination
was based upon comparisons against an external standard,
measured in parallel. All results were expressed as cross-
links/creatinine (pmol/μmol). Mean precision performance
for the BIO-RAD Pyridinium-Crosslinks test given by the
manufacturer reached a percentage coefficient of variation
of 6.4% for PYD and 6.6% for DPD [25].
QUS
Achilles+ is a heel water-bath ultrasound system. Achilles+
generates a band of frequencies from 200 to 600 kHz. It
measures broadband ultrasound attenuation (BUA)
expressed in dB/MHz, with a reported standardized
coefficient of variation (SCV) of 5.8%, and the speed of
sound (SOS) expressed in m/s, with a SCVof 4.2% [26]. A
third variable, the stiffness index (SI) with a SCV of 2.6%,
is calculated automatically, using the equation:
Si ¼ 0:67 BUAð Þ þ 0:28 SOSð Þ  420, expressed as
a percentage of the values obtained by the manufacturer
in a young adult population [27].
The Sahara QUS is a dry system ultrasound using an oil-
based coupling gel. The frequencies of the ultrasounds
range from 200 to 600 kHz. The two calculated variables are
the BUA with a SCV of 4.4% and the SOS with a SCV of
4.3% [26]. An additional variable, the quantitative ultrasound
index (QUI) with a SCVof 3.2%, is calculated automatically,
using the equation: QUI ¼ 0:41 BUAþ SOSð Þ  571;
The Result of this equation is expressed in dimensionless
units [28].
Statistical analysis
Statistical tests used to compare fracture cases and controls
for each baseline characteristic were Student’s t tests and
Pearson’s chi square tests, as appropriate. To estimate the
predictive power of each test alone and of tests in
combination, with respect to discriminating non-vertebral
fractures, areas under the receiving operating characteristic
curves (AUC) were calculated with 95% confidence
intervals (95% CI). Differences in AUC of the predictive
scores derived from the logistic regression with combina-
tions of independent variables were tested statistically using
the algorithm described in Delong et al. [29]. As no
consensus exists about the threshold values for increased
bone turnover, we studied two commonly used thresholds,
the highest quartile against the three lowest and the
premenopausal upper reference limit. The peak values for
the premenopausal range were generated by the BIO-RAD
laboratory kit and have been defined as per the Center for
Disease Control and Prevention in Atlanta [25]. Similarly,
because of the lack of established risk thresholds for QUS
in clinical practice, we studied two different threshold
values for each QUS device, the lowest quartile against the
three highest, and a cutoff value that was able to detect,
with a specificity of 80%, women at high-risk for fracture
or with known osteoporosis of the hip in the SEMOF
cohort [20]. According to these thresholds, we estimated
odds ratios (OR) with 95% CI for those with high versus
low bone marker levels and for those with low versus
high QUS measurements. We estimated OR for serial
(i.e., consecutive) combinations of the two diagnostic tests,
using the ‘and’ logical operator. All analyses were
performed using Stata 9.2 statistical software (Stata
Corporation, College Station, TX, USA).
Results
Baseline characteristics of the 195 non-vertebral fracture
patients and 173 controls are presented in Table 1. Mean
age was 76.2±3.2 years. Women who had sustained a non-
vertebral fracture had statistically higher levels of bone
resorption markers and lower QUS measurements than
controls. As the prevalence of past fracture was not
statistically different between fracture patients and controls,
and adjusted OR for this factor were comparable to non-
adjusted OR (data not shown), we did not enter this
variable into the logistic model. In sub-analyses, consider-
ing women with arm fractures only, there were no statistical
differences in DPD levels compared to controls (data not
shown).
For each individual test—PYD, DPD, SOS, BUA, SI,
and QUI—the AUC revealed an overall discriminatory
capacity for the hip or arm fracture group (Table 2). Sahara
QUI had the higher discriminatory power, with an AUC
(95%CI) of 0.65 (0.59–0.71); however, no test was
statistically better than the other. As the discriminatory
capacity of the different QUS parameters was not statisti-
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cally different, we showed only the Achilles+ SI and the
Sahara QUI for combined strategies. The combinations of
bone markers and QUS (Achilles+ SI or Sahara QUI)
increased the AUC slightly but without statistically signif-
icant changes compared to either test alone. In sub-
analyses, the discriminatory power was higher for all tests
when only the hip fracture subgroup was considered, with
PYD exhibiting the highest AUC (0.75; 0.69–0.82); but,
again, no single test was statistically better than any other.
The combination of PYD and QUS was statistically better
than QUS alone to discriminate between hip fracture
patients and controls; however, this combination was not
better than PYD alone (Table 2 and Fig. 1). Considering the
arm fracture subgroup only, PYD and DPD were not
discriminatory (data not shown).
Table 3 shows OR with 95% CI and the number of
women exposed to fractures versus women without fractures,
associated with defined cutoffs for PYD, DPD, SI, and QUI.
For PYD and DPD, the peak limits were >92.2 and
17.8 pmol/μmol for the highest quartile, and >63 and 13.5
pmol/μmol for the premenopausal range, respectively. For
the Achilles+ SI and Sahara QUI, the risk thresholds were
≤57 (%) and ≤57.9 (unit) according to the lowest quartile,
and ≤59.1 (%) and ≤63 (unit) according to Hans et al. [20],
respectively. Women with levels of bone markers above the
highest quartile or the upper limit of the premenopausal
Table 2 Area under the receiver operating-characteristic curve (AUC) for predictive models of law-trauma non-vertebral fractures, with 95%
confidence intervals (95%CI)
Hip or arm fracture group (95% CI) Hip fractures group (95% CI)
Urinary markers of bone resorption PYD 0.62 (0.56–0.68) 0.75 (0.69–0.82)
DPD 0.59 (0.53–0.65) 0.70 (0.63–0.78)
Achilles+ heel ultrasound BUA 0.61 (0.55–0.67) 0.69 (0.62–0.77)
SOS 0.64 (0.58–0.69) 0.68 (0.60–0.76)
SI 0.64 (0.58–0.69) 0.70 (0.63–0.78)
Sahara heel ultrasound BUA 0.64 (0.58–0.69) 0.68 (0.60–0.75)
SOS 0.65 (0.60–0.71) 0.70 (0.62–0.78)
QUI 0.65 (0.59–0.71) 0.69 (0.62–0.77)
Combination Achilles+ and markers SI and PYD 0.66 (0.60–0.71) 0.76* (0.69–0.83)
SI and DPD 0.65 (0.59–0.70) 0.74 (0.66–0.81)
Combination Sahara and markers QUI and PYD 0.68 (0.62–0.73) 0.76** (0.69–0.83)
QUI and DPD 0.67 (0.61–0.72) 0.74 (0.66–0.81)
BUA broadband ultrasound attenuation, SOS speed of sound, SI stiffness index, QUI quantitative ultrasound index, DPD deoxypyridinoline, PYD
pyridinoline
*p<0.05 compared to Achilles+SI alone, **p<0.05 compared to Sahara QUI alone
Table 1 Baseline characteristics of low-trauma fracture patients and controls
Control group Hip or arm fracture
group
P
valuea
Hip fracture
group
P
valuea
Number 173 195 62
Age, years 76.3±3.2 76.2±3.1 0.78 76.9±3.0 0.18
BMI, kg/m2 25.3±4.3 25.5±4.1 0.63 24.3±4.2 0.10
History of past fracture 46.2 (80) 54.4 (106) 0.14 53.2 (33) 0.34
Urinary markers of bone
resorption
PYD, pmol/µmol 73.1±23.5 85.9±33.3 0.00 99.6±36.7 0.00
DPD, pmol/µmol 14.6±6.1 16.4±7.3 0.01 19.0±9.1 0.00
Achilles+ heel ultrasound BUA, dB/MHz 99.4±10.0 95.1±9.4 0.00 92.1±8.7 0.00
SOS, m/s 1509.3± 28.6 1495.6 ± 24.2 0.00 1490.9±26.9 0.00
SI, % 68.9± 13.4 62.2 ±12.0 0.00 59.0±12.1 0.00
Sahara heel ultrasound BUA, dB/MHz 57.2±16.8 49.1±12.7 0.00 47.0±12.6 0.00
SOS, m/s 1517.2±29.4 1501.9±22.1 0.00 1499.1±25.8 0.00
QUI, unit 74.5±18.4 64.9±13.7 0.00 62.9±15.1 0.00
Values are reported as mean ± standard deviation or percentage (number)
BMI body mass index, BUA broadband ultrasound attenuation, SOS speed of sound, SI stiffness index, QUI quantitative ultrasound index, DPD
deoxypyridinoline, PYD pyridinoline
a Comparison between fracture patients and controls
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range were at increased risk of sustaining a non-vertebral
fracture, with OR of about 2. Achilles+ SI was significantly
predictive only when the highest quartile was considered and
was slightly less predictive than the Sahara device. Because
DPD was less predictive than PYD, data on the combination
of QUS and bone markers are given only for PYD. The
combinations of bone markers and QUS increased slightly
the prediction of fracture with both risk threshold strategies,
but with larger confidence intervals. Considering the hip
fracture subgroup and the quartiles as high-risk thresholds,
the combination of PYD and QUS (either Achilles+ SI or
Sahara QUI) had a higher predictive capacity than QUS
alone; but it was not better than PYD alone (Table 3).
Discussion
In this nested case-control study including elderly women,
we found that two urinary markers of bone resorption, total
PYD and total DPD, and two heel QUS, Achilles+ and
Sahara, discriminate between low-trauma non-vertebral
fracture patients and controls with about the same capacity.
Combining the two QUS with bone resorption markers did
not discriminate better than a single test between those at
risk and those not at risk. Considering the hip fracture
subgroup only, adding the measurement of urinary PYD to
a heel QUS determination improved discriminatory perfor-
mance of QUS alone, but not of PYD alone.
Markers of bone resorption
Bone resorption markers evaluate osteoclastic activity,
which is the rate of bone destruction [3]. PYD and DPD
are bone matrix components which stabilize the collagen
molecule. They are released in the bloodstream and
excreted in the urine during bone resorption. Of the
different markers and measurement methods available, we
used in this analysis total urinary PYD and DPD, both
assessed by means of HPLC. Nowadays, direct immuno-
assays for PYD and DPD are widely used. The discrimi-
natory power of PYD and DPD assessed by HPLC can be
extrapolated to immunoassays currently in use, as results
of immunoassays reported for total PYD and DPD are
highly correlated with those measured by HPLC (r=0.97
for PYD ; r=0.95 for DPD) [30, 31]. However, in clinical
practice, the results of our study should not be extrapolated
to guide the use of new serum resorption markers, like the
Elecsys® β-CrossLaps for example, as unpublished data
from Roche Diagnostics have revealed only moderate
correlation between urinary PYD or DPD (r about 0.7). In
the SEMOF cohort, serum bone markers were not measured
mainly for two reasons. First, urinary sampling is a safe,
non-invasive and easily performed technique. When evalu-
ating a screening test, simplicity and acceptability for
patients are important criteria, and obtaining blood samples
in the SEMOF cohort was difficult as most of the
participants refused blood collection. Second, because the
PYD and DPD found in urine largely are derived from
skeletal tissues, independent of alimentation [32], at the time
the protocol for the current study was drafted in 1997, these
tests were considered the most sensitive markers of bone
resorption [33].
We found that elderly women with high levels of bone
resorption markers were predisposed to osteoporotic frac-
tures with an OR of about 2. These results were consistent
with previous studies, where high levels of bone markers
(above the median, higher quartile, or levels above the
premenopausal range) have been shown to contribute to
fracture probability in elderly women [4–10] However,
some recent reports have shown controversial results. In a
prospective cohort study, Gerdhem et al. failed to identify
any predictive capacity of urinary free DPD, measured by
Fig. 1 Receiver operating characteristic (ROC) curves for the
discrimination of hip fractures with heel quantitative ultrasounds and
urinary marker of bone resorption. Achilles+ SI stiffness index; PYD
pyridinoline; Sahara QUI quantitative ultrasound index. a Combina-
tion of Achilles+ SI and PYD; b Combination of Sahara QUI and
PYD
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immunoassay, during a mean 4.6 years of follow-up for
osteoporosis fractures in ambulatory elderly women [34].
Examining different bone turnover markers, Chen et al.
found no difference between fracture cases and controls in
older women and men living in residential care facilities
[35]; and, in a convenient prospective cohort of elderly
women with known osteoporosis and receiving treatment,
Glüer et al. detected no difference between patients with or
without incident vertebral fractures [36]. Mainly because of
the large pre-analytical variability of bone markers and
differences in the populations studied, comparing the
results of these reports is fraught with difficulty.
No generally accepted threshold exists to define “high
turnover rate,” and most current guidelines do not give
clear recommendations for the clinical use of bone
resorption markers. To address this concern, we investigat-
ed different thresholds for bone markers. The upper limit of
premenopausal range is a convenient and clinically appli-
cable threshold. Values were provided by a laboratory kit,
and they were less elevated than the median for PYD and
about the same as the median for DPD. Thus, bone marker
levels above the highest quartile identified patients at high
risk for fracture and appeared to be more predictive than
using the upper limit of premenopausal range because of
the smaller number of patients detected. However, when
interpreting the results in light of confidence intervals, there
was no difference between threshold strategies. At the
opposite end, a lower cutoff may be used when the goal is
to rule out any increased risk of fracture. Our data show that
the absence of any elevation in PYD above the premeno-
Table 3 Odds Ratios (OR) with 95% confidence intervals (95% CI) for non-vertebral fracture prediction and number (N) of women in each
model for a urinary marker of bone resorption [pyridinoline (PYD)] and two heel quantitative ultrasounds [Achilles+ stiffness index (SI) and
Sahara quantitative ultrasound index (QUI)], associated with various risk thresholds
Quartile OR (95 % CI) Positive test Negative test
High PYD>92.2 pmol/μmol; high DPD>17.8 pmol/μmol Fracture patients (N)/controls
(N)
Fracture patients (N)/controls
(N)Low SI≤57 %; low QUI≤57.9 unit
Hip or arm fracture group (195 fractures/173 controls)
High PYD 2.4 (1.5–4.0) 62/28 133/145
High DPD 2.2 (1.3–3.6) 61/30 134/143
Low Achilles+ SI 1.9 (1.2–3.1) 61/33 134/140
Low Achilles+ SI and high PYD 4.1 (1.6–10.2) 25/6 170/167
Low Sahara QUI 2.4 (1.5–4.0) 62/28 133/145
Low Sahara QUI and high PYD 5.4 (2.0–14.4) 27/5 168/168
Hip fracture group (62 fractures/173 controls)
High PYD 4.6 (2.4–8.7) 29/28 33/145
High DPD 4.2 (2.2–7.9) 29/30 33/143
Low Achilles+ SI 3.3 (1.7–6.1) 27/33 35/140
Low Achilles+ SI and high PYD 11.4 (4.3–30.4) 18/6 44/167
Low Sahara QUI 3.3 (1.7–6.3) 24/28 38/145
Low Sahara QUI and high PYD 11.7 (4.1–33.6) 16/5 46/168
Defined risk threshold
High PYD>63 pmol/μmol; high DPD>13.5 pmol/μmol: upper limit of premenopausal range
Low SI≤59.1%; low QUI≤63 unit: thresholds from Hans et al. [20]
Hip or arm fracture group (195 fractures/173 controls)
High PYD 2.0 (1.3–3.1) 149/107 46/66
High DPD 1.7 (1.1–2.6) 119/82 76/91
Low Achilles+ SI 1.5 (1.0–2.4) 71/47 124/126
Low Achilles+ SI and high PYD 1.9 (1.2–3.1) 60/33 135/140
Low Sahara QUI 2.1 (1.4–3.2) 99/57 96/116
Low Sahara QUI and high PYD 2.4 (1.5–3.8) 168/125 27/48
Hip fracture group (62 fractures/173 controls)
High PYD 7.0 (2.7–18.4) 57/107 5/66
High DPD 3.8 (2.0–7.4) 48/82 14/91
Low Achilles+ SI 2.5 (1.4–4.6) 30/47 32/126
Low Achilles+ SI and high PYD 4.0 (2.1–7.4) 30/33 32/140
Low Sahara QUI 3.2 (1.8–5.9) 38/57 24/116
Low Sahara QUI and high PYD 5.1 ( 2.7–9.4) 37/39 25/134
for non-verteb al f acture p edicti and number (N) of wom n in each
model for a urinary m rker of bone resorption [pyridinoline (PYD)]
a d two heel quantitative ultrasounds [Achilles+ sti fness i dex (SI)
and Sahara quan tative ultrasound index (QUI)], associated with
various risk thresholds
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pausal range in elderly women strongly decreases the
probability of hip fracture, as only five women with a
negative test sustained a hip fracture.
We also found that PYD was slightly more discrimina-
tive for the hip or arm fracture group than DPD.
Physiologically, DPD is more specific for bones than
PYD [37], so that a higher discriminatory capacity should
have been expected. However, previous studies comparing
the discriminatory power of PYD and DPD for postmen-
opausal osteoporosis have been inconsistent [38–40].
Combining markers of bone resorption and heel
quantitative ultrasound
The use of heel QUS together with PYD added nothing to
either test performed alone with respect to detecting women
at risk for low-trauma non-vertebral fractures. However, in
subgroup analysis, for the discrimination of hip fractures
only, our results suggest that increased bone resorption
might add complementary information to QUS measure-
ments, identifying high-risk patients who were missed by
QUS. To our knowledge, this improvement in the discrim-
inatory capacity of the serial combination of QUS and
bone resorption markers has not been evident in other
studies. Garnero et al. found that the serial detection of
C-telopeptide breakdown products (CTX) above the pre-
menopausal range and low BMD is an improvement over
the accuracy of a single test as a predictor of hip fracture,
but they found no advantage of combining heel ultrasound
and CTX [11]. However, in our study, performing PYD
assessment alone would be as discriminative as the
combination of the both PYD and QUS. Moreover, the
apparent contrast between the AUC results, demonstrating
no additive value when QUS and resorption markers are
combined, and the large OR for those with both low QUS
and high resorption markers, with quartile as threshold,
might be explained by the consecutive selection of a small
number participants at very high-risk of fracture, represent-
ing a small proportion of the study participants, as reflected
by the large confidence intervals of OR (Table 3).
Considered the gold standard for osteoporosis assess-
ment, BMD was not measured in the SEMOF cohort.
Instead, we used different heel QUS as the reference tests
for fracture prediction. However, heel QUS has been
proven to predict osteoporotic fractures as well as BMD
measurements in elderly women [27, 28, 41], and because
QUS is relatively inexpensive, transportable, and ionizing
radiation-free, there is a growing interest in its use in many
countries. High levels of correlation (r>0.8) have been
reported between Achilles and Sahara parameters. The
Achilles QUS is considered the “reference device” [26],
because of its use in most of the validation studies. In our
analyses, we found that Achilles+ SI was slightly less
discriminatory than Sahara QUI. Cross-sectional studies
comparing the two devices uncovered better results with
Achilles+ SI for hip fracture prediction [21, 42], but the
results are inconsistent for vertebral fracture prediction [43].
Our study has limitations. Urine sample collection was
standardized, so as to control for the timing of collection;
nonetheless, because significant diurnal variations exist in
the levels of biochemical bone markers, within-subject
variability could not be avoided completely. The day-to-day
variation in the urinary excretion of PYD and DPD also is
reported to be a major source of within-subject variability
[44], which also could affect the reproducibility of results.
AUC and OR were higher in the hip fracture subgroup than
in the hip or arm fracture group. This increased predictive
ability could be related to more advanced osteoporosis in
women who subsequently sustain a hip fracture. This
difference in severity of disease may have improved the
prediction power. Thus, the results we obtained within the
hip fracture subgroup should not be extrapolated to justify
similar screening in populations with less advanced disease.
In addition, the number of hip fractures investigated was
relatively low, so that the confidence intervals were broad.
This reflects the need for cautious interpretation of our results
when considering any individual patient. Finally, cases and
controls were matched on BMI, and its effect on QUS
measurements or bone turnover assessments have not been
investigated. Possible overmatching could have reduced the
differences observed between cases and controls.
Strategies to improve the identification of women at risk
for fracture are being developed, using multiple risk factors,
including clinical risk factors, QUS, and BMD measure-
ments [45]. Our study increases the quantity of evidence
supporting the relatively equal capacity of urinary bone
resorption markers and heel QUS to detect elderly ambulant
women at risk for low-trauma non-vertebral fractures
relative to matched controls. However, the serial combina-
tion of the both tests added no complementary discrimina-
tory information compared to either test used alone. These
data, in turn, may help in the design of efficient strategies to
evaluate fracture risk in elderly women.
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